89242-16-0

Basic information

• Product Name: 4-benzylidene-2-(3-chlorophenyl)-1,3-oxazol-5(4H)-one
• CAS NO: 89242-16-0
• Molecular Formula: C₁₆H₁₀ClNO₂
• Molecular Weight: 283.7091
• Mol File: 89242-16-0.mol

Chemical Properties

• Boiling Point: 420.4°C at 760 mmHg
• Flash Point: 208.1°C
• Density: 1.27g/cm³
• Vapor Pressure: 2.82E-07mmHg at 25°C
• Refractive Index: 1.623
• CAS DataBase Reference: 4-benzylidene-2-(3-chlorophenyl)-1,3-oxazol-5(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-benzylidene-2-(3-chlorophenyl)-1,3-oxazol-5(4H)-one(89242-16-0)
• EPA Substance Registry System: 4-benzylidene-2-(3-chlorophenyl)-1,3-oxazol-5(4H)-one(89242-16-0)

Safety Data

• Hazardous Substances Data: 89242-16-0(Hazardous Substances Data)

Upstream product

• 57728-59-3 m-chlorobenzene carboxamidoacetic acid 
• 100-52-7 benzaldehyde 

Relevant articles and documents

Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents

As a continuation of our previous work, a series of new phenyl acrylamide derivatives (4Aa-g, 4Ba-t, 5 and 6a-c) were designed and synthesized as non-nucleoside anti-HBV agents. Among them, compound 4Bs could potently inhibit HBV DNA replication in wild-type and lamivudine (3TC)/entecavir resistant HBV mutant strains with IC50 values of 0.19 and 0.18 μM, respectively. Notably, the selective index value of 4Bs was above 526, indicating the favorable safety profile. Interestingly, unlike nucleoside analogue 3TC, 4Bs could significantly inhibit 3.5 kb pgRNA expression. Molecular docking study revealed that 4Bs could fit well into the dimer-dimer interface of HBV core protein by hydrophobic, π–π and H-bond interactions. Considering the potent anti-HBV activity, low toxicity and diverse anti-HBV mechanism from that of nucleoside anti-HBV agent 3TC, compound 4Bs might be a promising lead to develop novel non-nucleoside anti-HBV therapeutic agents, and warranted further investigation.

Compounds having an aryltriazine structure

A compound having an aryltriazine structure selected from those of formula (I): STR1 for which the meaning of the substituents Ar, R1, R5, R6, and R6 ' is given in the description. The compound of the invention is useful as medicinal product for disorders associated with a cholinergic dysfunction.